Literature DB >> 14679110

Her2-neu: a target in lung cancer?

F Andre, T Le Chevalier, J C Soria.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14679110     DOI： 10.1093/annonc/mdh033

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

1.  Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer.

Authors:  Johan Vansteenkiste; Jean-Luc Canon; Henrik Riska; Robert Pirker; Patrick Peterson; William John; Pekka Mali; Michael Lahn
Journal:  Invest New Drugs       Date:  2005-06       Impact factor: 3.850

2.  Expression proteomics study to determine metallodrug targets and optimal drug combinations.

Authors:  Ronald F S Lee; Alexey Chernobrovkin; Dorothea Rutishauser; Claire S Allardyce; David Hacker; Kai Johnsson; Roman A Zubarev; Paul J Dyson
Journal:  Sci Rep       Date:  2017-05-08       Impact factor: 4.379

3.  Epidermal growth factor receptor status and Notch inhibition in non-small cell lung cancer cells.

Authors:  Efstathia Giannopoulou; Achilleas Nikolakopoulos; Dimitra Kotsirilou; Angeliki Lampropoulou; Sofia Raftopoulou; Evangelia Papadimitriou; Achilleas D Theocharis; Thomas Makatsoris; Konstantinos Fasseas; Haralabos P Kalofonos
Journal:  J Biomed Sci       Date:  2015-10-24       Impact factor: 8.410
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.